Lawsuit Spurs Debate Over PCAST Meetings: Should They Be Open To Press And Public?

Some researchers question the aura of secrecy that surrounds the presidential panel's closed-door sessions on science policy Scientists around the United States appear to be at loggerheads over the question, brought to the fore by a recent lawsuit, of whether the President's Council of Advisers on Science and Technology (PCAST) should be conducting a greater portion of its work in meetings that are open to the press and public. On one hand, some, including PCAST members, say that discussing

Written byBarton Reppert
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

On one hand, some, including PCAST members, say that discussing such potentially sensitive matters as AIDS research and bio- diversity in closed meetings enables the council members to be more candid and objective in offering their advice to President Bush and the Office of Science and Technology Policy (OSTP). Closed meetings, they say, also allow for more give-and-take of contrasting views within the group, formed by the administration in early 1990.

WASHINGTON, D.C.--Election-year politics was sprinkled amid science issues as the President's Council of Advisers on Science and Technology (PCAST) convened here for its regular June meeting, dealing with issues including the superconducting supercollider (SSC) and federally funded AIDS research. A portion of the meeting was ordered open to the public by a United States District Court judge in Washington. In contrast to the panel's previous practice, the open portion of the meeting was expanded to include both the morning ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies